Analyst consensus rating
Ascendis Pharma Analyst Rating: Strong Buy
ASND is rated Strong Buy by 19 analysts with a $313.40 target. As of 2026-08-22.
Direct answer
Ascendis Pharma's consensus rating is Strong Buy.
19 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $313.40.
Forecast evidence checked August 22, 2026.
Get free Ascendis Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $253.29
- Average price target
- $313.40
- High price target
- $364.41
- Low price target
- $263.71
- Low target gap
- +4.1%
- Target upside
- +23.7%
- High target gap
- +43.9%
- Target range width
- 39.8%
- Consensus rating
- Strong Buy
- Analysts
- 19
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ascendis Pharma?
Ascendis Pharma has a verified Strong Buy consensus. The same dataset has an average price target of $313.40.
How far are Ascendis Pharma's low and high targets from the recorded price?
The low target implies +4.1%, while the high target implies +43.9%.
How many analysts are included in Ascendis Pharma's consensus?
The verified consensus includes 19 analysts.
How is Ascendis Pharma's target upside or downside calculated?
The average target of $313.40 is divided by the recorded price of $253.29, then one is subtracted to produce +23.7%. This does not guarantee a future return.
When was Ascendis Pharma's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.